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Recently, deregulation of the expression of proto-oncogenes
belonging to the growth factor receptor family with intrinsic thyro-
sine kinase activity, has been reported in SSs. Co-expression of c-
MET and HGF/SF and expression of IgF-1R has been shown in SS
surgical specimens, the former by immunocytochemistry (Fukuda
et al, 1998; Motoi et al, 1998; Kuhnen et al, 1998; Oda et al, 2000),
by Western blotting (Wb) and by RT-PCR (Fukuda et al, 1998;
Oda et al, 2000) and the second by Wb and RT-PCR (Xie et al,
1999). In accordance with the epithelial differentiation driving role
of c-MET in the c-MET-HGF/SF system, c-MET immunoreac-
tivity has been mainly found in the epithelial component of
tumours (Fukuda et al, 1998; Motoi et al, 1998; Kuhnen et al,
1998; Oda et al, 2000), even though, by virtue of its role in the
promotion of progression, the co-expression of HGF and c-Met
has been recently correlated with poor prognosis in SSs (Oda et al,
2000). Moreover, in keeping with the role played by IgF-IR in
tumour cell growth, its expression has been found to be signifi-
cantly associated with a high incidence of lung metastases (Xie 
et al, 1999). 
The proto-oncogene c-Kit was identified as the cellular homo-
logue of the oncogene c-Kit present in the genome of Hardy-
Zuckerman 4-feline sarcoma virus that induces multicentric
fibrosarcoma in domestic cats (Besmer et al, 1986). This proto-
oncogene encodes a tyrosine kinase receptor which bears a region
homologous with platelet-derived growth factor and colony stimu-
lating factor 1 receptor (Yarden et al, 1987; Qui et al, 1987). The
ligand for c-Kit product has been cloned and variously designated as
stem cell factor (SCF) (Besmer et al, 1986), mast cell growth factor,
kit ligand or steel factor (Williams et al, 1990; Copeland et al, 1990;
Nocka et al, 1990). SCF-Kit interaction is essential for the develop-
ment of melanocytes, germ cells and mast cells (Galli et al, 1993). 
Beyond a c-Kit role in cellular proliferation and differentiation
(Torihashi et al, 1999), c-Kit is involved in protecting cells from
apoptosis (Ricotti et al, 1998) as demonstrated in neuroblastoma
(Timeus et al, 1997). 
Recently, a role of KIT mutations and c-Kit/SCF mRNA over-
expression in the development of sarcomas has been suggested
(Ricotti et al, 1998; Hirota et al, 1998). A constitutively activated
mutated c-Kit protein has been demonstrated in 5 out of 49
gastrointestinal stromal tumours (GISTs) (Hirota et al, 1998)
currently regarded to originate from the putative intestinal cell of
Cajal on the basis of immunophenotypic (Hirota et al, 1998;
Kindblom et al, 1998) and ultrastructural features (Kindblom et al,
1998). Subsequently, an identical somatic and germ-line c-Kit
mutation was found in a patient and in her nephew both suffering
from multiple GISTs (Nishida et al, 1998) and, more recently, in a
mother and her natural daughter (Hirota et al, 2000). At present,
after the seminal Hirota’s report, there is no consensus on the
frequency of c-Kit gene mutations in sporadic GISTs, ranging
from 21 % (Moskaluk et al, 1999) to more than 50% (Lasota et al,
1999) although the expanded observations share the evidence of a
high correlation between malignancy and c-Kit mutation.
Nevertheless, virtually all GISTs with and without mutations,
showed CD 117 immunoreactivity (Moskaluk et al, 1999, Lasota 
et al, 1999). Furthermore, the mRNA co-expression of c-Kit-SCF,
possibly related to an autocrine loop able to protect the cells from
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Summary In a previous immunophenotypic molecular-based analysis it was shown that bcl2 over-expression characterizes the SS gene
profile in addition to the non-random translocations. Here we show that the over-expression of an additional potentially antiapoptotic gene, the
c-KIT gene, is associated with this tumour. Interestingly, whereas bcl2 over-expression appears to be restricted to the spindle cell tumoral
component, c-kit mainly involves the epithelial component of biphasic SS. Twenty-three primary and metastatic samples from 21 patients
were analysed by immunophenotyping (23/23), immunoprecipitations and Western blotting (3/23), and RT-PCR (23/23). Ten cases were
biphasic and 13 monophasic in sub-type. Twelve, 10 and 1 case carried the SYT-SSX1, SYT-SSX2 and SYT-SSX4 fusion transcript,
respectively. Co-presence of both c-Kit and SCF mRNA was observed in almost all cases (20/23), suggesting the occurrence of an autocrine
loop. Immunophenotyping, confirmed by biochemical analyses, showed a modulation of c-Kit expression which was faint in the spindle and
strong in the epithelial component, respectively. The study was complemented by c-Met/HGF receptor/ligand expression and c-Met protein
analysis with results superimposable to those already reported. Since in each tumour, epithelial and spindle cell components harbour the
same type of translocation t(X;18) the present findings suggest a shifting of the anti-apoptotic role from BCL2 to c-KIT gene during the
transition from the uncommitted spindle to the differentiated epithelial cells. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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(Ricotti et al, 1998). 
Here we report the expression of the c-Kit gene and its ligand
SCF, complemented by the c-Met/HGF gene system expression
and c-Kit/c-Met immunophenotype in a series of synovial
sarcomas (SS) already known to carry the non-random t(X;18) and
over-expressing the protein encoded by the master inhibitory gene
bcl2 (Mancuso et al, 2000). 
MATERIALS AND METHODS 
Tumours and patients
A total of 23 synovial sarcomas from 20 patients were analysed in
this study. There were 11 primary tumours, 2 local tumour relapses
and 10 pulmonary metastases: 9 to the lung and 1 to the adrenal
gland. Cases 19 and 20 had both primary tumour (19a, 20a) and
metastasis (19b, 20b and 20c). Anatomical location of primary
tumours is detailed in Table 1. 
Morphologically, 10 cases were biphasic and 13 monophasic in
sub-type. A total of 12 cases showed the fusion transcript SYT-
SSX1, 10 cases the SYT-SSX2 transcript and 1 the SYT-SSX4
one. All the SS cases in the study but 4 (case nos 7, 9, 20a and 20c)
have been previously reported (Mancuso et al, 2000). 
Cell lines 
The human megakaryoblastic leukaemia M07e cell line was
kindly provided by Prof. L Pegoraro and was kept in culture as
described by Brizzi et al, JBC 1994 (Brizzi et al, 1994). It was
used as positive control for c-Kit and SCF expression. 
FL-EBV cell line, derived from the fetal liver of a health donor
immortalized with Epstein–Barr Virus, kindly provided by Dr
Domenico Delia, was used as positive control for c-Met and HGF
genes expression and was maintained in culture with 15% FCS
RPMI in standard conditions. 
RNA extraction and reverse transcriptase polymerase
reaction (RT-PCR) 
Total RNA was extracted using the RNAzol method (Gibco BRL,
Life Technology) from snap-frozen tumour tissue samples stored
at –80˚C. 1 mg of RNA was reverse-transcribed into cDNA using
oligo (dT) primers and reverse transcriptase (Superscript II Gibco
BRL, Paisley, UK) according to the manufacturer’s recommenda-
tions. The integrity of cDNA was detected by the amplification of
the housekeeping b-actin gene (Adams et al, 1995). One ml of
cDNA was used as template for each PCR reaction. 
SYT-SSX PCR 
The detection of the putative SYT-SSX1 and SYT-SSX2 was
carried out with the following primers: 
SYT 5¢-CAACAGCAAGATGCATACCA-3¢
SSX1 5¢-GGTGCAGTTGTTTCCCATCG-3¢
SSX2 5¢-GGCACAGCTCTTTCCCATCA-3¢
PCR conditions were: 35 cycles of denaturation at 94˚C for 30 s,
annealing at 58˚C for 1 min and elongation at 72˚C for 1 min
(Kawai et al, 1998). 
The detection of fusion transcript SYT-SSX4 was performed by
a nested PCR with the following primer pairs: 
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Table 1 Summary of the data 
Patient Sample  Age / sex Morphologic Fusion
No. analysed site sub-types transcript  c-Kit SCF c-Kit c-met HGF c-met
SYT-SSX mRNA ICC mRNA ICC 
1 P 48/F thigh Biphasic 4 +  +LS + + +  +
2 P 36/F leg Monophasic 2 +  +LS + + +  +
3 P 18/M neck Biphasic 1 +  +LS + + +  +
4 P 46/F thigh Monophasic 1 +  +LS + + +  +
5 P 48/M shoulder Monophasic 2  + +L + +  +  –
6 P 39/F thigh Monophasic 2 +  +LS + + –  +
7 P 12/M abdominal wall Biphasic 2  + +L + +  –  +
8 P 50/F elbow Biphasic 2 +  +L + + +  –
9 P 18/F sub-mandibular Biphasic 1  + +LS + +  +  +
region
10 R 52/F shoulder Biphasic 2  + +LS + +  +  +
11 R* 63/F groin Monophasic 1  + +LS + +  +  +
12 AM* 51/F thigh Monophasic 1  + +L + +  –  +
13 PM* 30/M thigh Monophasic 2  + +LS + +  +  +
14 PM* 54/F ankle Monophasic 1  – – + – –  +
15 PM* 20/F leg Monophasic 1 +  +LS + + –  +
16 PM* 54/G arm Monophasic 2 +  +LS + + +  NE
17 PM* 30/M elbow Biphasic 1 +  +LS + + +  +
18 PM* 55/M shoulder Monophasic 1  + +LS + +  +  +
19a P 16/F buttock Monophasic 2  – – + – –  +
19b PM* 18 Monophasic 2 + +L NE + –  NE
20a P 16/F thigh Biphasic 1 +  +L + + –  +
20b PM* 19 Biphasic 1 – – + – –  +
20c PM* 20 Biphasic 1 + +LS + + +  +
ICC = immunocytochemical analysis; P = primary tumour; R = local tumour ; PM = pulmonary metastasis; AM = adrenal gland metastasis;
L = long form of SCF; S = short form of SCF; NE = no valuable; samples marked with an asterisk are from pre-treated patients. SYT external 5¢-CAACAGCAAGATGCATACCA-3¢
SSX¢¢ 5¢-TGCTATGCACCTGATGACGA-3¢
The annealing temperature was 52˚C for 1 min. 
SYT internal 5¢-AGACCAACACAGCCTGGACCA-3¢
SSX4¢¢ 5¢-GGCACAGCTGTTTCCCATCA-3¢
The annealing temperature was 58˚C for 1 min. 
The amplification products of all the translocation breakpoints
were analysed on 2% agarose gel in TAE1X buffer. 
One of each fusion type transcript (SYT-SSX1, SYT-SSX2 and
SYT-SSX4) was sequenced and used as positive control. 
c-Kit and SCF PCR 
The c-Kit mRNA expression was evaluated using the primers
(Ricotti et al, 1998) 
5¢ forward GAGTTGGCCCTAGAAGTTAGA 
5¢ reverse CCTGGAGGTGGATGCAAGTT 
at the following conditions: 40 cycles at 94˚C for 1 min., 64˚C 
for 45 s, 72˚C for 1 min. 
For its ligand, SCF, the amplification was carried out with the
following primers 
5¢ forward ATTCAAGAGCCCAGAACCCA 
5¢ reverse CTGTTAACCAGCCAATGTACG 
The PCR conditions were: 40 cycles at 94˚C for 1 min., 63˚C 
for 45 s, 72˚C for 1 min. The use of AmpliTaq Gold was
recommended. 
c-Met and HGF PCR 
c-Met receptor was amplified using the following primers
(Moryama et al, 1995): 
5¢ forward ACAGTGGCATGTCAACATCGCT 
5¢ reverse GCTCGGTAGTCTACAGATTC 
The used conditions were: 5 cycles 94˚C 1 min, 58˚C 2 min, 72˚C
2 min, 30 cycles 94˚C for 30 s, 59˚C for 1 min, 72˚C for 1 min. 
The ligand HGF, was amplified using the primers 
5¢ forward GGGAAATGAGAAATGCAGCCAG 
5¢ reverse AGTTGTATTGGTGGGTGCTTC 
with the same conditions of c Met, using AmpliTaq Gold instead. 
Protein extraction 
Proteins were extracted from tissue samples stored at –80˚C, by
homogenization at 4˚C in lysis buffer (50 mM Tris-HCl pH 7.5, 
5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40) supplemented
with protease inhibitors. Lysis was performed by frequent
vortexing, followed by sonication step. Protein lysates were then
cleared by centrifugation at 14 000 rpm at 4˚C for 30 min and
quantitated through BCA analysis (Pierce, Rockford, USA). 
Immunoprecipitations and Western blotting 
Equal amounts of lysates were subjected to immunoprecipitation
by incubating with 3 ml of mouse monoclonal antibody Ab-3
(K45) (NeoMarkers, Union City, CA), directed against the c-Kit
receptor, even if it was conjugated to its receptor (SCF). The M07e
cell line lysate, with overexpressed c-Kit receptor, was used as
positive control while the lysate from normal human synovia was
used as the negative one. After a 2 h incubation with the specific
antibody, at 4˚C and under gentle agitation, the protein complexes
were incubated for 1 h with protein A Sepharose (Sigma, St.
Louis, USA) at 4˚C with gentle agitation. Immunoprecipitates
were then collected by centrifugation and washed three times with
the same buffer supplemented with antiproteases. Next, the
immunoprecipitated material was boiled for 5 min in Laemli
buffer (62 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 0.003%
bromophenole blue) and analysed by SDS-PAGE electrophoresis
under reducing conditions on a 10% acrylamide minigel (Biorad,
Richmond, CA). Coloured Rainbow protein markers (Amersham,
UK) were used. 
Proteins were transferred to a polyvinyldene difluoride
membrane and subjected to Western blotting. The membrane was
saturated with 4% BSA (Amersham) for 2 h at room temperature.
c-Kit protein was detected with a rabbit polyclonal antibody (C-
19, Santa Cruz Biotecnology, CA, USA) diluted 1:200 in TBS (20
mM Tris-HCl pH 7.5, 154 mM NaCl). The secondary antibody
was used at the recommended dilution (Sigma). Specific bands
corresponding to the investigated proteins were detected using a
chemioluminescent technique, according to the manufacturer’s
recommendations (ECL detection system, Amersham). 
Immunoprecipitation experiments against the b-actin protein
were performed as previously described using 1 ml of the specific
polyclonal antibody (Sigma) and using all the unbound total
proteins derived form the c-Kit immunoprecipitation experiments.
The subsequent Western blot was incubated with a mouse mono-
clonal b-Actin antibody (Sigma) diluted 1:5000. 
Immunocytochemical (ICC) analysis 
ICC study was performed by the streptavidine-peroxidase conju-
gated method (Shi et al, 1998). The following primary antibodies
were applied: anti c-Kit polyclonal rabbit antibody (C-19, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti c-Met polyclonal
rabbit antibody (C-12, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), the monoclonal Bcl2 antibody (mouse clone 124, kindly
donated by Dr Mason, Department of Histopathology, London
University College) to paraffin-embedded sections using 1:100
and 1:50 dilutions, and 1:20 respectively. 
The specificity of the primary antibodies c-Met and c-Kit were
confirmed by the use of specific peptides (sc-168 P, Santa Cruz,
for c-Kit and sc-10 P, Santa Cruz, for c-Met). Competition experi-
ments were performed as follow: diluted antibody (1:50) was
preincubated with 4 mg of the specific peptide and incubated at
37˚C for 2 h and then utilized at the working dilution following
standard procedures. 
Cytokeratin positivity was detected using a pool of antibody
constituted by 34 bE12 (Dako) and KS 8.12 (Sigma) diluted
1:200, following standard procedures. 
RESULTS 
Since, according to a recent report (Zhang et al, 1998) human mast
cells can be a cellular source of SCF, and SS is known to bear in
some cases a relevant number of this type of cell (Ueda et al,
1988), an evaluation of this cellular component has been
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the spindle cell component in some areas of surgical material
sections in six cases (three biphasic and three monophasic) of SSs
(case nos 3, 10, 13, 14, 16 and 20b of Table 1). However, none of
the control sections of cryopreserved material showed a significant
mast-cell component. 
SCF and c-Kit RNA expression 
The mRNA of the c-Kit gene was detected in all the analysed
samples but case nos 14, 19a and 20b of Table 1 (Figure 1A) and
this expression profile parallels well with SCF mRNA expression.
On a total of 20 positive cases, 14 tumours showed the specific
SCF bands (494 bp and 409 bp, named L and S respectively) and 6
tumours (n. 5, 7, 8, 12, 19b and 20a) showed only the higher SCF
band (L) (Figure 1B). The positive control M07e cell line
displayed mRNA for both c-Kit receptor and its ligand represented
by the two specific bands. 
c-Kit Immunoistochemical analysis 
The immunostaining intensity was faint, diffuse and cytoplasmic
in the spindle cells of monophasic SSs. In biphasic tumours a
definite enhancement of reactivity was observed in the epithelial
component which paralleled the switch off of the immunoreac-
tivity of the spindle cells intermixed with or surrounded the
epithelial nests/structures in most of the cases (Figures 2A and
2B). 
Such an immunoreactivity was inhibited by the pre-incubation
of the antibody with a specific synthetic peptide against which the
antibody was raised. 
Cytokeratin positivity, like c-Kit staining, was restricted to the
epithelial cells (Figures 2E and 2F). 
Immunoprecipitation of c-Kit receptor 
Three cases where a large amount of frozen material was avail-
able, were chosen for immunoprecipitation experiments. 
A band of 150 kDa, comigrating with the positive control of the
c-Kit of M07e cell line, was detected in two biphasic synovial
sarcomas (case nos 7 and 20a of Table 1) but not in one
monophasic synovial sarcoma (case no. 11 of Table 1) and in the
normal human synovia (Figure 3). As control, the bound proteic
material derived form c-Kit IP was secondly immunoprecipitated
with a specific antibody for b-Actin protein. The intensity of the
detected band (50KDa) was identical in all the analysed cases
(Figure 3). These results correlated to the ICC data even if case
11 showed both a c-Kit mRNA expression and reactivity with
immunistochemical analysis. 
HGF and c-Met RNA expression 
All cases were tested for the presence of HGF mRNA. Fourteen
tumours showed the presence of the expected band and nine cases
resulted negative (case nos 6, 7, 12, 14, 15, 19a, 19b, 20a and 20b
of Table 1) (Figure 1D). 
c-Met mRNA receptor was found in all tumours but cases 14,
19a and 20b (Figure 1C). 
In six cases (6, 7, 12, 15, 19b and 20a) only the presence of
c Met RNA, not associated to the presence of its ligand, HGF
mRNA, was detected. 
c-Met immunoistochemical analysis 
All the analysed tumours were positive but case nos 5 and 8 even
if a mRNA expression was detected for both c-Met gene and its
ligand. Two cases were not assessable cases (16 and 19b). 
The areas overexpressing c-Met corresponded to the epithelial
component of biphasic SSs, however a faint reactivity was present
in the spindle cell component of both biphasic and monophasic
tumours in accordance with previous reports (Kuhnen et al, 1998). 
mRNA expression data (RT-PCR) (Table 1) did not show any
correlation with pathologic stage (primary vs metastasis), histo-
logic sub-type, fusion transcript and anatomical localization. 
DISCUSSION 
In this study, 23 cases of primary and metastatic synovial
sarcomas, 10 biphasic and 13 monophasic in sub-type, were
analysed. We investigated the expression of c-Kit and its ligand,
SCF, in addition to c-Met tyrosine kinase receptors and its ligand,
HGF, by analysing the presence of related mRNAs. Western blot
and immunocytochemical analysis were also performed thus
confirming at protein level the expression of the two receptors. 
To our knowledge, the present report is the first study that
underlines the presence of the c-Kit/SCF system in SSs.
Immunocytochemical analysis showed that the overexpression of
this receptor is mainly restricted to the epithelial component of
biphasic SSs. Accordingly, the band detected by immunoprecipita-
tions and Western blot, corresponding to the c-Kit receptor, was
only found in the proteic lysate obtained from two biphasic
tumours and not in the monophasic one. The weak c-Kit expres-
sion observed in the monophasic subtype was probably insufficient
to be detected by this technique. Unfortunately, due to the delayed
snap-freezing of the tumour material, we were unable to assess the
phosphorylation status of the receptor. Comparing the presence of
408 E Tamborini et al 
British Journal of Cancer (2001) 85(3), 405–411 © 2001 Cancer Research Campaign
c-Kit
SCF
c-Met
HGF
bp
1018
517
1018
517
1018
517
517
298
M C+ 123456789 1 0 1 1 1 2 1 3 1 4 1 5
Figure 1 RT-PCR analysis. RNA was reverse transcribed and the obtained
cDNA was subjected to specific PCR. PCR products were run in a 1.8%
agarose gel and photographed under UV light. Lane 1s to 14 correspond to
case nos 1, 2, 3, 4, 5, 6, 7, 8, 11, 13, 14, 19a, 20a and 20c of Table 1. (A)
mRNA expression of c-Kit. The detected band of 749 bp corresponds to c-Kit
receptor. C+: as positive control mRNA from M07e cell line was used. (B)
mRNA expression of SCF. Two bands of 494 and 409 bp corresponding to L-
SCF and S-SCF respectively, were detected. C+: as positive control mRNA
from M07e cell line was used. (C) mRNA expression of c-Met. A band of 656
bp corresponding to c-Met receptor was detected. C+: as positive control
mRNA from FL-EBV was used. (D) mRNA expression of HGF. A band of
315–303 bp corresponding to HGF was detected. C+: as positive control
mRNA from FL-EBV was used both c-Kit and SCF mRNA we always observed a correlation
between them: their tight association suggests therefore the exis-
tence of a possible autocrine loop in this type of tumour and we
could thus hypothesize that the latter express a wild-type receptor.
On the contrary, in the GISTs model, the constitutive phosporylation
of the c-Kit receptor is due to point mutations in the exon 11 (Hirota
et al, 1998), and makes redundant the production of the ligand, SCF,
whose expression was always detected in our tumours.
In most of our cases, we identified two SCF isoforms, here
defined L and S. The S isoform, lacking exon 6, encodes a
membrane-bound SCF while isoform L encodes a protein
containing a cleavage site that makes the ligand susceptible to
post- translational proteolysis, yielding a soluble SCF. Both
isoforms are biologically active (Anderson et al, 1990; Toskoz 
et al, 1992) but the mechanisms that control the tissue-specific and
developmentally regulated production of SCF L vs SCF S are not
well understood. In our SS series, we never detected the S isoform
alone but we found the co-presence of the two isoforms L and S or
the L form alone. The expression of c-Kit and of its ligand SCF,
both as L or S form, did not show any segregation either to the
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Figure 2 ICC analysis. (A) Light expression of c-Kit in spindle cells of a monophasic SS (Table 1, case 6) (× 200). (B) Strong c-Kit cytoplasmic decoration
restricted to epithelial component of a biphasic SS (Table 1, case 9) with evidence of switch off of c-Kit immunoreactivity in the surrounding spindle cells (× 200).
(C) The same case showing bcl2 immunoreactivity reastricted to the spindle cell component (× 200). (D) Monophasic SS bcl2 stained (Table 1, case 5) (× 200).
(E) Dot-like cytokeratin immunoreactivity which appears to parallel the weakness in bcl2 and the gain in c-Kit immunostaining in a monophasic SS with a plump
cell component (× 200). (F) the same SS c-Kit immunodecorated (× 200) pathologic tumour stage, histologic sub-type, fusion transcript, or
anatomical localization. The possibility that the SCF mRNA
transcripts in our cases were not derived from tumour cells but
from contaminating mast cells (Ueda et al, 1988) was ruled out by
the microscopic control on frozen sections of cryopreserved
samples before molecular analysis. 
The presence of c-Kit oncogene and its ligand, SCF, was
recently reported in pPNETs (Ricotti et al, 1998). This finding is
not unexpected since we know that undifferentiated SS may share
some morphologic and immunophenotypic characteristics with
pPNETs (Dei Tos et al, 1995; Folpe et al, 1998; van de Rijn et al,
1999) and that, though rarely, SSs may show pPNET featuring
components (Mezzelani et al, 1998; Noguera et al, 1998). 
A concomitant mRNA expression of HGF and c-Met genes was
firstly reported in cell lines derived from other tumours of
mesenchymal origin, such as a human glioma (Moryama et al,
1995) and human osteosarcoma cell lines (Cooper et al, 1984).
More recently, c-Met protein expression was reported in two
different series of SSs (Motoi et al, 1998; Kuhnen et al, 1998). In
order to complement our c-Kit data, we investigated the expres-
sion of c-Met and its ligand, HGF, along with c-Met protein.
Although our molecular results did not completely fit in with the
immunocytochemical ones and some discrepancies need further
investigation, immunophenotyping results were superimposable to
those already described by Kuhnen and colleagues. We detected in
fact, a strong expression of c-Met gene product in the epithelial
component and a faint reactivity in the spindle cell one. Since it is
currently conceived that each SS epithelial and spindle tumour cell
harbours the same type of translocation t(X;18) (Clark et al, 1994),
the evidence that the two TK related genes, c-Met and c-Kit, even
though more expressed in the biphasic SS are also expressed in
monophasic subtype, gives further support to the hypothesis that
the two SS subtypes may truly represent a ‘carcinosarcoma’ with
differently developed epithelial component (Leader et al, 1987;
Miettinen et al, 1984). 
Cumulatively, the current evidence suggests that the non- random
SS translocation t(X;18) may trigger the transactivation of a cascade
of genes such as c-Met, c-Kit, and their ligands, yielding two
different autocrine loops: the first acting on the epithelial differenti-
ation and the second working in a program protecting from apop-
tosis (Timeus et al, 1997). Since in a previous study (Mancuso et al,
2000) we have shown that a Bcl2 over-expression is a part of the SS
gene profile and this expression, at variance with c-Kit receptor, is
mainly restricted to the spindle cell component, the scenario that can
be envisaged might be as follows. The epithelial differentiation
process is driven by the c-Met gene and this driving parallels the
shifting of the antiapoptotic role from Bcl2 to the c-Kit gene during
transition from the spindle uncommitted to the epithelial differenti-
ated cells. The shifting is in keeping with the tight correlation
between the cell type and both modulation of expression and
specific localization of the c-Kit gene product we observed. In fact,
in biphasic SS the faint decoration of the spindle cells tends to disap-
pear in the spindle, albeit Bcl2 positive, cells, surrounding the
epithelial areas to which the strongest c-Kit immunoreactivity is
restricted (Figure 2A–C) and the cytokeratin positivity confirm this
shifting (Figure 2E). Moreover, primary biphasic tumours may
reoccur as monophasic SSs (Mancuso et al, 2000). Again this does
not appear a contradictory finding since the modulations and
changes of morphologic features that occur and that we observed
during recurrences or metastatic progression, may be ascribed to the
dynamic plasticity of the expression of the involved genes. 
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